ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
MWN-AI** Summary
Allergan Aesthetics, a division of AbbVie, has recently unveiled data illustrating significant shifts in patient profiles and treatment demands in the realm of Medical Weight Loss (MWL) treatments. A substantial 67% of MWL patients now prioritize aesthetic improvements, such as facial appearance, rather than merely focusing on weight reduction. The data reveals that nearly half of the patients express a need for hyaluronic acid (HA) injectable fillers to address facial changes stemming from rapid weight loss.
As more consumers utilize GLP-1 medications—used for weight loss—60% now source these from providers offering concurrent aesthetic treatments, a notable increase from prior statistics. This indicates a growing intersection between weight loss and aesthetic medicine, with many patients experiencing concerns linked to facial volume and skin texture post-weight loss.
The landscape of aesthetic care is evolving, with 61% of GLP-1 users reporting issues like midface volume loss and 50% citing skin laxity as primary concerns. HA fillers are recognized as crucial treatments, with 81% of healthcare providers (HCPs) identifying them as a top nonsurgical solution following weight loss. Furthermore, approximately one-third of physicians noted an uptick in dermal filler injections associated with GLP-1 treatment, reflecting an increase in overall patient demand for aesthetic procedures.
Allergan Aesthetics is committed to addressing these emerging patient needs through education, insights, and consultations. As more individuals seek comprehensive solutions to restore facial balance and confidence after weight loss, the integration of aesthetic treatments within weight management practices becomes increasingly vital. This growth highlights both a changing patient demographic and evolving treatment paradigms in the aesthetic and weight loss landscape.
MWN-AI** Analysis
The latest data from Allergan Aesthetics regarding Medical Weight Loss (MWL) highlights significant shifts in patient demographics and treatment preferences that investors and market analysts should closely monitor. The findings indicate a burgeoning interest among MWL patients in aesthetic treatments, particularly as they transition into weight loss success. Approximately 67% of patients assert that MWL has transformed their goals from merely losing weight to enhancing their appearance, signaling a more comprehensive approach to wellness and self-image.
This evolving landscape presents a lucrative opportunity for aesthetic providers. Nearly half of MWL patients report the need for hyaluronic acid injectable fillers to address post-weight loss facial concerns. As the data reveals, 61% of GLP-1 medication recipients experience midface volume loss, underscoring the critical role of facial volume restoration in post-MWL treatment plans. Given that 81% of healthcare providers identify hyaluronic acid fillers as a top nonsurgical treatment modality in this context, businesses that provide such services are well-positioned for growth.
Furthermore, the trend showing 60% of consumers obtaining GLP-1 medications from providers who also offer aesthetic treatments indicates that cross-selling opportunities are emerging. As aesthetic treatments increasingly become a staple for patients undergoing MWL, relevant healthcare providers should consider integrating these offerings to capture this expanding demographic.
In summary, the convergence of MWL and aesthetic treatments not only aligns with the demand for individualized, long-term care but also represents a shift in patient priorities. Investors in the health and beauty sector should consider this transition as a potential growth driver, particularly for companies focusing on comprehensive aesthetic solutions. Continuous monitoring of these trends will be crucial for leveraging opportunities in this evolving market space.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Data shows a rise in specific treatment demand; a shift in patient consultation and the rising role of facial volume restoration
- 67% of patients say MWL treatment changed their goals toward improving appearance, not just weight reductioni.
- Nearly half of MWL patients (47%) were reported by HCPs to benefit most from hyaluronic acid injectable fillers when addressing post-weight-loss facial concernsii.
- 60% of consumers receiving GLP-1 medications obtain them from providers who also offer aesthetic treatments, up from 49% in late 2024iii.
IRVINE, Calif., March 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, shares new data illustrating how the rapid adoption of Medical Weight Loss (MWL) treatments is changing patient behavior, aesthetic priorities, and treatment demand, particularly as facial volume loss emerges as a leading concern.
"Allergan Aesthetics is committed to equipping our customers with data-driven insights, education, and consultation tools to help guide patients safely and effectively through these changes," said Glen Curran, Senior Vice President at Allergan Aesthetics. "We're seeing this new patient population enter aesthetics with different concerns, different goals, and a strong desire for individualized, long-term treatment and care, particularly when it comes to restoring facial balance and volume."
Data Highlights: How GLP-1–Associated Weight Loss Is Changing Aesthetic Care
The data underscores a broader evolution in the aesthetics landscape; patients undergoing medical weight loss are entering aesthetic practices with distinct needs tied to facial volume, structure, and skin quality, many for the first time. As rapid weight loss can accelerate visible changes in the face, early consultation and proactive treatment planning are critical to helping patients understand their options and achieve balanced, natural looking outcomes. For many of these patients, hyaluronic acid fillers can play an important role in addressing volume loss and supporting natural-looking outcomes that align with their overall transformation journey.
Consumer interest in aesthetics is rising with 40% of MWL patients considering a professionally administered aesthetic treatment in a physician's office or medspaiv. Notably, aesthetic practices are increasingly serving as an entry point into the category; 60% of consumers using GLP-1 medications now receive them from healthcare providers who also offer aesthetic treatments, up from roughly half just one year agov.
According to Allergan Aesthetics studies and consumer market research, physicians report that MWL is driving meaningful shifts in facial concerns, treatment preferences, and patient demand:
- Facial volume loss is the leading aesthetic impact, with 61% of GLP-1 patients experiencing midface volume loss, followed by skin laxity (50%), and facial wrinkles/folds (35%)vi.
- Hyaluronic acid (HA) dermal fillers are a primary treatment option, with 81% of HCPs identifying HA fillers as a top nonsurgical modality following GLP-1 related weight lossvii.
- One-third of physicians (33%) say GLP-1 usage has increased the overall volume of dermal filler injections in their practiceviii.
Allergan Aesthetics has been studying the intersection of MWL and aesthetic medicine since early 2022. Allergan Aesthetic consumer market research closely mirrors data the company presented at the 2025 American Society for Dermatologic Surgery (ASDS) Annual Meeting and was published in January 2026 in the Aesthetic Surgery Journal's Open Forum, "Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations," demonstrating that patients are increasingly seeking physician-guided aesthetic solutions to address changes in facial appearance following weight loss.
"As a dermatologist, I've seen firsthand how medical weight loss can significantly impact the face," said Dr. Joely Kaufman, a board-certified dermatologist in Miami, FL. "This data reflects what we're seeing in practice – patients who are excited about their weight loss success are looking for personalized, medically appropriate solutions that restore balance and confidence."
Through proprietary consumer research, physician collaboration, and data shared at leading medical forums, the company continues to translate emerging trends into actionable insights for healthcare providers.
Download our MWL & Aesthetics infographic to learn more.
Media Contact
Kate McShane
Director, Corporate Communications
Cell +1862.325.6984
Email Kate.McShane@allergan.com
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
*An AbbVie company
i Allergan Aesthetics, July 2024, GLP-1 Consumer Study | |||||||
ii Survey of Facial Aesthetic Concerns and Treatment Trends Following GLP-1 Agonist-Associated Weight Loss, Allergan Aesthetics and AbbVie, American Society for Dermatologic Surgery 2025, Chicago, IL | |||||||
iii Allergan Aesthetics 2025 Consumer Aesthetic Tracker – Key Findings for Q3 2025: Quantitative Research with Consumers | |||||||
iv Allergan Aesthetics Weight Loss Treatment: Patient Interest and Types of Treatments, June 2025 Assessment | |||||||
v Allergan Aesthetics 2025 Consumer Aesthetic Tracker – Key Findings for Q3 2025: Quantitative Research with Consumers | |||||||
vi Survey of Facial Aesthetic Concerns and Treatment Trends Following GLP-1 Agonist-Associated Weight Loss, Allergan Aesthetics and AbbVie, American Society for Dermatologic Surgery 2025, Chicago, IL | |||||||
vii Survey of Facial Aesthetic Concerns and Treatment Trends Following GLP-1 Agonist-Associated Weight Loss, Allergan Aesthetics and AbbVie, American Society for Dermatologic Surgery 2025, Chicago, IL | |||||||
viii Allergan Aesthetics Weight Loss Treatment: Patient Interest and Types of Treatments, June 2025 Assessment |
SOURCE AbbVie
FAQ**
How is AbbVie Inc. ABBV leveraging the recent data showing that 67% of Medical Weight Loss patients have shifted their focus toward improving appearance to enhance their product offerings and marketing strategies?
With nearly half of MWL patients benefiting from hyaluronic acid injectable fillers, how is AbbVie Inc. ABBV planning to expand its product line to cater to the evolving demands of this patient demographic?
Given that 60% of consumers receiving GLP-1 medications are now obtaining them from providers offering aesthetic treatments, what strategies does AbbVie Inc. ABBV have in place to integrate MWL and aesthetic services within its marketing framework?
As patients increasingly seek personalized aesthetic treatments following weight loss, what initiatives is AbbVie Inc. ABBV implementing to ensure healthcare providers are equipped to address these changing patient concerns effectively?
**MWN-AI FAQ is based on asking OpenAI questions about AbbVie Inc. (NYSE: ABBV).
NASDAQ: ABBV
ABBV Trading
0.21% G/L:
$228.2209 Last:
2,045,501 Volume:
$226.05 Open:
